Page last updated: 2024-12-05
2-trifluoromethylbenzoic acid
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9899 |
| CHEBI ID | 60694 |
| SCHEMBL ID | 221518 |
| MeSH ID | M0190796 |
Synonyms (57)
| Synonym |
|---|
| nsc-88326 |
| nsc88326 |
| 433-97-6 |
| o-carboxybenzotrifluoride |
| .alpha.,.alpha.,.alpha.-trifluoro-o-toluic acid |
| 2-trifluoromethylbenzoic acid |
| ENAMINE_005364 |
| NCIOPEN2_001264 |
| 2-(trifluoromethyl)benzoic acid, 98% |
| 2-(trifluoromethyl)benzoic acid , |
| AC-2625 |
| AKOS000118808 |
| HMS1409D18 |
| CHEBI:60694 |
| o-(trifluoromethyl)benzoic acid |
| 2-tfmba |
| o-trifluoromethylbenzoic acid |
| 2-(trifluoroformyl)benzoic acid |
| ortho-(trifluoromethyl)benzoic acid |
| o-(trifluoroformyl)benzoic acid |
| FT-0695424 |
| T1302 |
| alpha,alpha,alpha-trifluoro-o-toluic acid |
| 137938-95-5 |
| trifluoromethylbenzoic acid |
| 2-trifluromethylbenzoic acid |
| STK946190 |
| nsc 88326 |
| benzoic acid, 2-(trifluoromethyl)- |
| unii-0r1ck7mzua |
| 0r1ck7mzua , |
| einecs 207-093-9 |
| FT-0608957 |
| AM61555 |
| SCHEMBL221518 |
| o-toluic acid, .alpha.,.alpha.,.alpha.-trifluoro- |
| mfcd00002476 |
| SY002327 |
| 2-trifluoromethyl-benzoic acid |
| ortho-trifluoromethylbenzoic acid |
| o-trifluoromethyl-benzoic acid |
| 2-trifluoromethyl benzoic acid |
| W-106233 |
| BS-4039 |
| benzoic acid,(trifluoromethyl)- |
| F2191-0057 |
| Z56922112 |
| 2-(trifluoromethyl)benzoicacid |
| Q27128431 |
| CS-W015913 |
| DTXSID90870537 |
| EN300-17349 |
| AC7509 |
| o-toluic acid, ?,?,?-trifluoro- (6ci,7ci,8ci); 2-(trifluoromethyl)benzoic acid; nsc 88326; o-(trifluoromethyl)benzoic acid; ?,?,?-trifluoro-o-toluic acid |
| A913683 |
| 2-(trifluoromethyl)benzoic;a,a,a-trifluoro-o-toluic acid;alpha,alpha,alpha-trifluoro-o-toluic acid |
| jpcuzpkblyuqrd-uhfffaoysa-n |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| benzoic acids | Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. |
| (trifluoromethyl)benzenes | An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (1)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 29.76
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (29.76) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||